
Sepsis- Pipeline Insight, 2024
Description
Sepsis- Pipeline Insight, 2024
DelveInsight’s, “Sepsis- Pipeline Insight, 2024” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Sepsis: Overview
Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Sepsis is sometimes called septicemia or blood poisoning. If not recognized early, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality. Sepsis develops when the immune system releases the chemicals in the bloodstream to fight an infection cause inflammation throughout the entire body instead.
Sepsis cannot spread to other people. Sepsis can be a result of an infection, and some infections can be spread to others. Most sepsis is caused by bacterial infections. It can also be a result of other infections, including viral infections, such as COVID-19 or influenza. An infection of the bone, called osteomyelitis, could lead to sepsis. In people who are hospitalized, bacteria may enter through IV lines, surgical wounds, urinary catheters, and bed sores. Sepsis is more common in people with chronic medical conditions, such as diabetes, lung disease, cancer, and kidney disease, people with weakened immune systems, babies under 1 year of age, elderly people especially if they have other health problems. Most of the time, using a thermometer, it is pretty simple to determine heart rate (counting pulses per minute), fever, or hypothermia, as well as to count breaths per minute even at home. Although it may be more challenging to identify the source of the infection, sepsis is generally simple to detect in people who have symptoms of infection including a productive cough, dysuria, fevers, or a wound filled with pus. Septic shock is the most severe complication of sepsis and carries high mortality.
Symptoms of septic shock are similar to those of severe sepsis, but it also include a significant drop in blood pressure. This drop in blood pressure can lead to heart failure, stroke, and failure of other organs, respiratory failure, and even death. In addition to the three stages of sepsis, several phases are exist within the first stage of sepsis. The late phase of sepsis is dominated by immune suppression, leading to the hypothesis that the immune system changes from hyper-inflammatory to hypo-inflammatory phases during sepsis. Treatment for sepsis is most effective when started early. Health workers watch for concerning signs and use tests to diagnose sepsis. They will then work to find the source of the infection. Early use of antimicrobials to treat bacteria, parasites, fungus or viruses is essential to improve outcomes from sepsis.
Low blood pressure is treated by intravenous fluids and sometimes medicines called vasopressors, which can increase blood pressure. Antibiotic resistance can make treatment more difficult.
""Sepsis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis.
This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sepsis Emerging Drugs
- Thymosin alpha 1: SciClone Pharmaceuticals
- Enibarcimab: AdrenoMed AG
- M 6229: Matisse Pharmaceuticals
- SNIPR 001: SNIPR Biome
Further product details are provided in the report……..
Sepsis: Therapeutic Assessment
This segment of the report provides insights about the different Sepsis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Sepsis
- There are approx. 30+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. phase III include, SciClone Pharmaceuticals.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Sepsis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.
Sepsis Report Insights
- Sepsis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Sepsis drugs?
- How many Sepsis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sepsis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sepsis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sepsis and their status?
- What are the key designations that have been granted to the emerging drugs?
- SciClone Pharmaceuticals
- AdrenoMed AG
- Matisse Pharmaceuticals
- SNIPR Biome
- Tianjin Chase Sun Pharmaceutical
- Beijing Scitech-Mq Pharmaceuticals
- Recce Pharmaceuticals
- Inotrem
- Octapharma
- Shaperon
- Shionogi
- Pharmazz
- Seres Therapeutics
- Thymosin alpha 1
- Enibarcimab
- M 6229
- SNIPR 001
- Kukoamine B
- ST-1830
- RECCE 327
- Nangibotide
- OctaplasLG
- HY209
- Cefiderocol
- Centhaquine
- SER 155
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Sepsis: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Sepsis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Thymosin alpha 1: SciClone Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Enibarcimab: AdrenoMed AG
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- M 6229: Matisse Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- SNIPR 001: SNIPR Biome
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Sepsis Key Companies
- Sepsis Key Products
- Sepsis- Unmet Needs
- Sepsis- Market Drivers and Barriers
- Sepsis- Future Perspectives and Conclusion
- Sepsis Analyst Views
- Sepsis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.